بررسی سوء مصرف مواد و استعمال سیگار در بیماران مبتلا به کووید-19 و غیر کووید-19 در شهر کاشان

نوع مقاله : مقاله پژوهشی

نویسندگان

1 Department of Addiction Studies, School of Medical and Clinical Research Development Unit-Matini/Kargarnejad Hospital, Kashan University of Medical Sciences, Kashan, Iran.

2 Student Research Committee, Kashan University of Medical Sciences, Kashan, Iran.

3 Infectious Diseases Research Center, Kashan University of Medical Sciences, Kashan, Iran.

4 Student Research Committee, Kashan University of Medical Sciences, .Kashan, Iran

5 Department of Psychology, Allameh Tabataba'i University, Tehran, Iran.

6 Research Center of Addiction and Behavioral Sciences, Shahid Sadoughi University of Medical Sciences, Yazd, Iran.

7 Department of Addiction Studies, School of Medical and Clinical Research Development Unit-Matini/Kargarnejad Hospital, Kashan University of Medical Sciences, Kashan, Iran. Department of Pharmacology, School of Medicine, Kashan University of Medical Sciences, Kashan, Iran.

8 Student Research Committee, Kashan University of Medical Sciences, Kashan, Iran. Department of Addiction Studies, School of Medicine, Kashan University of Medical Sciences, Kashan, Iran.

چکیده

مقدمه: کرونا یکی از بزرگترین مشکلات بهداشتی در جهان است. مطالعات نشان می دهد که افراد سیگاری یا معتادان در برابر این ویروس، آسیب پذیرتر هستند. مطالعه حاضر فراوانی استعمال دخانیات و سوء مصرف مواد را در بین بیماران مبتلا به کووید-19 و سایر بیماران مورد ارزیابی قرار داد.
روش‌ کار: در این پژوهش 1400 شرکت‌کننده از شهر کاشان (700 بیمار در گروه کووید-19 و 700 نفر در گروه غیرکووید-19) وارد مطالعه شدند. سپس پرسشنامه تشخیص اعتیاد (ASSIST) را تکمیل کردند و اعتیاد آنها با کیت تشخیصی آزمایش شد. داده ها با استفاده از آزمون های تی مستقل، مجذور خی، آزمون دقیق فیشر و SPSS نسخه 17، تحلیل شدند.
یافته‌ها: شیوع مصرف سیگار و مصرف مواد، در گروه کووید-19 به ترتیب 4/19 درصد و 4/4 درصد (به ترتیب 0/23 درصد و 2/9 درصد در گروه غیر کووید-19) بود. تفاوت معنی داری در مصرف سیگار بین دو گروه مشاهده نشد (229/0P=) .نتایج نشان داد که فراوانی مصرف کنندگان مواد در گروه کووید-19 به طور معنی داری کمتر بود (008/0P=).  
نتیجه‌گیری: نتایج حاضر نشان داد که شیوع استعمال دخانیات در بیماران مبتلا به کووید-19 تفاوت معنی‌داری با سایر بیماران ندارد. جالب توجه است که شیوع سوء مصرف مواد در میان شرکت کنندگان مبتلا به کووید-19 به طور قابل توجهی کمتر از سایر بیماران بود. از آنجایی که انتظار می رفت تعداد افراد سیگاری یا مصرف کننده مواد در بین بیماران مبتلا به کووید-19 بیشتر باشد، علت این تضاد، نامشخص است و برای روشن شدن ابعاد مختلف آن به مطالعات بیشتری نیاز است.

کلیدواژه‌ها

مراجع

  1. Hu B, Guo H, Zhou P, Shi Z-L. Characteristics of SARS-CoV-2 and COVID-19. Nat Rev Microbiol 2021; 19(3): 141-54.
  2. Wei PF, National Health Commission and National Administration of Traditional Chinese Medicine. Diagnosis and treatment protocol for novel coronavirus pneumonia (trial version 7). Chin Med J (Engl) 2020; 133(9): 1087-95. 
  3. Alimohamadi Y, Sepandi M, Taghdir M, Hosamirudsari H. Determine the most common clinical symptoms in COVID-19 patients: A systematic review and meta-analysis. J Prev Med Hyg 2020; 61(3): E304-12.
  4. Sanyaolu A, Okorie C, Marinkovic A, Patidar R, Younis K, Desai P, et al. Comorbidity and its impact on patients with COVID-19. SN Compr Clin Med 2020; 2(8): 1069-76.
  5. Schlosser A, Harris S. Care during COVID-19: Drug use, harm reduction, and intimacy during a global pandemic. Int J Drug Policy 2020; 83: 102896.
  6. Dubey MJ, Ghosh R, Chatterjee S, Biswas P, Chatterjee S, Dubey S. COVID-19 and addiction. Diabetes Metab Syndr Clin Res Rev 2020; 14(5): 817-23.
  7. Volkow ND. Collision of the COVID-19 and addiction epidemics. Ann Intern Med 2020; 173: 61-2.
  8. Testino G. Are patients with alcohol use disorders at increased risk for Covid-19 infection? Alcohol Alcohol 2020; 55: 344-6.
  9. Becker WC, Fiellin DA. When epidemics collide: Coronavirus Disease 2019 (COVID-19) and the opioid crisis. Ann Intern Med 2020; 173: 59-60.
  10. Vardavas CI, Nikitara K. COVID-19 and smoking: A systematic review of the evidence. Tob Induc Dis 2020; 18: 20.
  11. Patanavanich R, Glantz SA. Smoking is associated with COVID-19 progression: A meta-analysis. Nicotine Tob Res Off J Soc Res Nicotine Tob 2020; 22(9): 1653-6.
  12. Olds JL, Kabbani N. Is nicotine exposure linked to cardiopulmonary vulnerability to COVID-19 in the general population? FEBS J 2020; 287(17): 3651-5.
  13. Leung JM, Yang CX, Tam A, Shaipanich T, Hackett T-L, Singhera GK, et al. ACE-2 expression in the small airway epithelia of smokers and COPD patients: Implications for COVID-19. Eur Respir J 2020; 55(5): 2000688.
  14. Smith JC, Sausville EL, Girish V, Yuan M Lou, Vasudevan A, John KM, et al. Cigarette smoke exposure and inflammatory signaling increase the expression of the SARS-CoV-2 receptor ACE2 in the respiratory tract. Dev Cell 2020; 53(5): 514-29.e3.
  15. Brake SJ, Barnsley K, Lu W, McAlinden KD, Eapen MS, Sohal SS. Smoking upregulates angiotensin-converting enzyme-2 receptor: A potential adhesion site for novel coronavirus SARS-CoV-2 (Covid-19).  J Clin Med 2020; 9(3): 841.
  16. Humeniuk R, Ali R, Babor TF, Farrell M, Formigoni ML, Jittiwutikarn J, et al. Validation of the Alcohol, Smoking And Substance Involvement Screening Test (ASSIST). Addiction 2008; 103(6): 1039-47.
  17. Hooshyari Z, Sadralssadat J, Sadralssadat L. [Estimation of validation and reliability of Screening Test of Tobacco, Alcohol and Addictive Drugs in Iran]. Research in addiction 2013; 7: 37-52. (Persian)
  18. Sheikhi F, Yousefian N, Tehranipoor P, Kowsari Z. Estimation of the basic reproduction number of Alpha and Delta variants of COVID-19 pandemic in Iran. PLoS One 2022; 17(5): e0265489.
  19. Oude Munnink BB, Koopmans M. Tracking SARS-CoV-2 variants and resources. Nat Methods 2023; 20(4): 489-90.
  20. Romero Starke K, Reissig D, Petereit-Haack G, Schmauder S, Nienhaus A, Seidler A. The isolated effect of age on the risk of COVID-19 severe outcomes: A systematic review with meta-analysis. BMJ Glob Health 2021; 6(12): e006434.
  21. Kalantari H, Tabrizi AHH, Foroohi F. Determination of COVID-19 prevalence with regards to age range of patients referring to the hospitals located in western Tehran, Iran. Gene Rep 2020; 21: 100910.
  22. Pinna G. Sex and COVID-19: A protective role for reproductive steroids. Trends Endocrinol Metab 2021; 32(1): 3-6.
  23. Hopkinson NS, Rossi N, El-Sayed-Moustafa J, Laverty AA, Quint JK, Freidin M, et al. Current smoking and COVID-19 risk: Results from a population symptom app in over 2.4 million people. Thorax 2021; 76(7): 714-22.
  24. Usman MS, Siddiqi TJ, Khan MS, Patel UK, Shahid I, Ahmed J, et al. Is there a smoker’s paradox in COVID-19? BMJ Evid Based Med 2021; 26(6): 279-84.
  25. Farsalinos K, Barbouni A, Niaura R. Systematic review of the prevalence of current smoking among hospitalized COVID-19 patients in China: could nicotine be a therapeutic option? Intern Emerg Med 2020; 15(5): 845-52.
  26. World Health Organization. Global Adult Tobacco Survey (GATS). Fact sheet China 2010. Available from: https://cdn.who.int/media/docs/default-source/ncds/ncd-surveillance/data-reporting/china/gats/en-tfi-china-gats factsheet-2010.pdf?sfvrsn=df210d51_3&download=true
  27. Farsalinos K, Barbouni A, Poulas K, Polosa R, Caponnetto P, Niaura R. Current smoking, former smoking, and adverse outcome among hospitalized COVID-19 patients: A systematic review and meta-analysis. Ther Adv Chronic Dis 2020; 11: 2040622320935765.
  28. Miyara M, Tubach F, Pourcher V, Morelot-Panzini C, Pernet J, Lebbah S, et al. Low incidence of daily active tobacco smoking in patients with symptomatic COVID-19. Qeios 2020; ID: WPP19W.3.
  29. Wang H, Yu M, Ochani M, Amella CA, Tanovic M, Susarla S, et al. Nicotinic acetylcholine receptor alpha7 subunit is an essential regulator of inflammation. Nature 2003; 421(6921): 384-8.
  30. Akerström S, Mousavi-Jazi M, Klingström J, Leijon M, Lundkvist A, Mirazimi A. Nitric oxide inhibits the replication cycle of severe acute respiratory syndrome coronavirus. J Virol 2005; 79(3): 1966-9.
  31. Mahdavi A, Aliramezany M. Addiction and Covid-19 Disease: Risks and misconceptions. Addict Health 2021; 13(1): 66-7.
  32. Saeedi M, Omrani-Nava V, Maleki I, Hedayatizadeh-Omran AA, Moosazadeh M, et al. Opium Addiction and COVID-19: Truth or false beliefs. Iran J Psychiatry Behav Sci 2020; 14(2): e103509.
  33. Wang QQ, Kaelber DC, Xu R, Volkow ND. COVID-19 risk and outcomes in patients with substance use disorders: Analyses from electronic health records in the United States. Mol Psychiatry 2021; 26(1): 30-9.
  34. Hudzik B, Nowak J, Zubelewicz-Szkodzinska B. Consideration of immunomodulatory actions of morphine in COVID-19 - Short report. Eur Rev Med Pharmacol Sci 2020; 24(24): 13062-4.
  35. Roshanravan N, Ghaffari S, Hedayati M. Angiotensin converting enzyme-2 as therapeutic target in COVID-19. Diabetes Metab Syndr Clin Res Rev 2020; 14(4): 637-9.
  36. Jamali Z, Emamian MH, Hashemi H, Fotouhi A. The association of opioid use disorder and COVID-19, a longitudinal study. Int J Prev Med 2022; 13: 157.
  37. Health Protection Surveillance Centre. Epidemiology of COVID-19 in Ireland daily reports 2020. Available from: https://www.hpsc.ie/a-z/respiratory/coronavirus/novelcoronavirus/casesinireland/archive/dailyepidemiologyofcovid-19inirelandreports2020/
  38. Riahi T, Sadeghzadeh-Bazargan A, Shokri S, Ahmadvand D, Hassanlouei B, Baghestani A, et al. The effect of opium on severity of COVID-19 infection: An original study from Iran. Med J Islam Repub Iran 2021; 35: 115.
  39. Ford R, Bammer G, Becker N. The determinants of nurses’ therapeutic attitude to patients who use illicit drugs and implications for workforce development. J Clin Nurs 2008; 17(18): 2452-62.
مجله اصول بهداشت روانی
دوره 25، شماره 4
مرداد و شهریور 1402
صفحه 263-269

فایل ها

هم رسانی

ارجاع به این مقاله

آمار